The Effect of Bevacizumab-Related Hypertension on the Prognosis of Patients with Colorectal Cancer and Non-Small Cell Lung Cancer

被引：0

作者：

Pan, Juhua ^{[1
]}

Zheng, Liangda ^{[2
]}

Liu, Binghui ^{[1
]}

You, Shuqing ^{[1
]}

Zheng, Weizhi ^{[1
]}

机构：

[1] Taizhou First Peoples Hosp, Dept Pathol, Taizhou 318020, Zhejiang, Peoples R China

[2] Taizhou First Peoples Hosp, Dept Hematol, Taizhou 318020, Zhejiang, Peoples R China

来源：

INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2022年 / 84卷

关键词：

Bevacizumab; hypertension; colorectal cancer; non-small cell lung cancer; prognosis;

D O I：

10.36468/pharmaceutical-sciences.spl.448

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

To study and analyze the effect of bevacizumab-related hypertension on the prognosis of patients with colorectal cancer and non-small cell lung cancer. The study randomly selected 100 colorectal cancer patients and 100 non-small cell lung cancer patients who received therapy in our hospital from October 2019 to October 2021. Among them, adopted intervention for 100 colorectal cancer patients with bevacizumab combined with cytotoxic drug chemotherapy and adopted intervention for 100 non-small cell lung cancer patients with bevacizumab combined with standard chemotherapy. Bevacizumab treatment has better therapeutic effect of hypertension on colorectal cancer patients than non-small cell lung cancer patients. Compared with colorectal cancer patients who received bevacizumab treatment, non-small cell lung cancer patients under bevacizumab treatment caused more adverse reactions. Among 100 colorectal cancer patients, the number of patients with bevacizumab-related hypertension in grade 1, grade 2 and grade 3 were 45, 12 and 23 respectively. Among 100 non-small cell lung cancer patients, the number of patients with bevacizumab-related hypertension in grade 1, grade 2 and grade 3 were 44, 25 and 20 respectively. Bevacizumab-related hypertension can improve the prognosis and efficacy of colorectal cancer and non-small cell lung cancer patients.

引用

页码：21 / 24

页数：4

共 50 条

[21] Intrapleural combination bevacizumab with cisplatin therapy for non-small cell lung cancer caused by non-small cell lung cancer
Du, Nan
Zhao, Hui
Wang, Haibin
Li, Xiaosong
Ma, Junxun
Fan, Zhongyi
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[22] Prognosis of Patients with Stage I Non-Small Cell Lung Cancer
Flores, C. J.
Chirinos, L.
Enriquez, D.
Schwarz, L. J.
Mas, L.
Rojas, V.
Aguilar, A.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1185 - S1185
[23] Prognosis of non-small cell lung cancer patients with brain metastasis
Ohhara, Yoshihito
Isobe, Hiroshi
Sato, Toshitaka
Ito, Kenichiro
Fuke, Satoshi
Kojima, Tetsuya
Saito, Hiroshi
Nishiura, Yoichi
ANNALS OF ONCOLOGY, 2015, 26 : 106 - 106
[24] Prognosis for non-small cell lung cancer patients with brain metastases
Kim, Junghyun
Lee, Sang-Min
Yim, Jae-Jun
Yoo, Chul Gyu
Kim, Young Whan
Han, Sung Koo
Yang, Seok-Chul
THORACIC CANCER, 2013, 4 (02) : 167 - 173
[25] Prognosis in Patients with Non-Small Cell Lung Cancer and Satellite Tumors
Kocaturk, C. I.
Gunluoglu, M. Z.
Cansever, L.
Dincer, I. S.
Bedirhan, M. A.
THORACIC AND CARDIOVASCULAR SURGEON, 2011, 59 (06): : 360 - 363
[26] Subtyping of Non-Small Cell Lung Cancer in the Era of Bevacizumab
Lang, T. U.
Navarro, P. A.
Weinstein, B.
Fraire, A. E.
Garcia-Moliner, M.
MODERN PATHOLOGY, 2009, 22 : 355A - 355A
[27] Subtyping of Non-Small Cell Lung Cancer in the Era of Bevacizumab
Lang, T. U.
Navarro, P. A.
Weinstein, B.
Fraire, A. E.
Garcia-Moliner, M.
LABORATORY INVESTIGATION, 2009, 89 : 355A - 355A
[28] The Use of Bevacizumab in Non-Small Cell Lung Cancer: An Update
Lauro, Salvatore
Onesti, Concetta Elisa
Righini, Riccardo
Marchetti, Paolo
ANTICANCER RESEARCH, 2014, 34 (04) : 1537 - 1545
[29] Bevacizumab: A new treatment for non-small cell lung cancer?
Clark, C
Gordon, J
ONCOLOGY NURSING FORUM, 2006, 33 (02) : 406 - 406
[30] Bevacizumab and non-small cell lung cancer: a new step?
Perol, M.
Arpin, D.
REVUE DES MALADIES RESPIRATOIRES, 2009, 26 (02) : 125 - 138

← 1 2 3 4 5 →